Objective-Migration of vascular smooth muscle cells (VSMCs) from the media into intima contributes to the development of atherosclerosis. Gene deletion experiments implicate a role for toll-like receptor 2 (TLR2) in atherogenesis. However, the underlying mechanisms remain unclear. We postulate that TLR2 promotes VSMC migration by enhancing interleukin (IL)-6 production. Methods and Results-Migration assays revealed that TLR2 agonists promoted VSMC migration but not cell proliferation or viability. TLR2 deficiency or inhibition of TLR2 signaling with anti-TLR2 antibody suppressed TLR2 agonist-induced VSMC migration and IL-6 production, which was mediated via p38 mitogen-associated protein kinase and extracellular signal-regulated kinase 1/2 signaling pathways. Neutralizing anti−IL-6 antibodies impaired TLR2-mediated VSMC migration and formation of filamentous actin fiber and lamellipodia. Blockade of p38 mitogen-associated protein kinase or extracellular signal-regulated kinase 1/2 activation inhibited TLR2 agonist pam3CSK4-induced phosphorylation of cAMP response element−binding protein, which regulates IL-6 promoter activity through the cAMP response element site. Moreover, cAMP response element−binding protein small interfering RNA inhibited pam3CSK4-induced IL-6 production and VSMC migration. Additionally, Rac1 small interfering RNA inhibited pam3CSK4-induced VSMC migration but not IL-6 production. Conclusion-Our results suggest that on ligand binding, TLR2 activates p38 mitogen-associated protein kinase and extracellular signal-regulated kinase 1/2 signaling in VSMCs. These signaling pathways act in concert to activate cAMP response element−binding protein and subsequent IL-6 production, which in turn promotes VSMC migration via Rac1-mediated actin cytoskeletal reorganization. 
A bnormal activation of the innate immune system and the resulting chronic inflammation have been implicated in the development and progression of chronic and metabolic diseases, including atherosclerosis. 1 Toll-like receptors (TLRs) are important components of the innate immunity. TLRs recognize diverse microbial pathogens, as well as endogenous ligands derived from damaged cellular or tissue constituents. 2 TLRs are implicated in atherosclerosis; expression of TLRs, especially TLR1, TLR2, and TLR4, is enhanced in human atherosclerotic plaque. Importantly, endogenous ligands for TLR2 have been detected in atherosclerotic plaque of apolipoprotein E−knockout mouse model and human coronary bypass grafts. [3] [4] [5] Atherosclerosis is retarded in TLR2 knockout mice, suggesting that TLR2 plays a critical role in progression of atherosclerosis and atheromatous plaque formation. 6, 7 These results further underscore the importance of TLR2 in atherosclerosis. However, it is unclear how TLR2 promotes atherosclerosis. Atherosclerosis is a complex chronic disease initiated with endothelial injury followed by immune and proinflammatory cell accumulation, lipid deposition, and progressive inflammatory responses. 1, 8 Smooth muscle cell migration, proliferation, and synthesis of proinflammatory cytokines and extracellular matrix are considered to be key events in atherosclerosis. 1, 8 Vascular smooth muscle cells (VSMCs) reside in the media of normal blood vessels where they are November 2012 quiescent and assume a contractile phenotype. 9, 10 In response to endothelial injury signals VSMCs migrate into the intima where they assume high proliferative and synthetic profile. 11 Furthermore, they contribute to vascular inflammation by producing proinflammatory cytokines, such as interleukin (IL) 6, IL-8, and vascular cell-adhesion molecule 1. 12 It was reported that vascular infection by Chlamydia pneumoniae induces proinflammatory cytokine release via TLR2. 13 Considering the influence of inflammation in atherogenesis and functional TLR2 promoting inflammation in SMCs, activation of TLR2 in VSMCs may have fundamental significance in VSMC survival, proliferation, and migration.
cAMP response element-binding protein (CREB) is a transcription factor that regulates diverse cellular responses, including proliferation, survival, and differentiation. CREB is induced by a variety of growth factors and inflammatory signals and mediates the transcription of diverse genes harboring cAMP response elements. 14, 15 Classically, the CREB functional state is regulated by phosphorylation at serine 133, which permits its binding to the coactivator protein CREBbinding protein and leads to increased CREB-mediated gene expression, including proinflammatory IL-6. Several protein kinases have been identified to phosphorylate and activate CREB. 14, 16 It has been reported that TLRs trigger CREB Ser-133 phosphorylation, thereby increasing CREB-mediated IL-6 transcription in immune cells. 16 CREB was reported to promote VSMC migration and proliferation, 15, [17] [18] [19] but the triggering mechanism is unclear. We postulated that TLR2 might regulate VSMC migration and proliferation through activation of CREB-mediated IL-6 production. To test this hypothesis, we evaluated the effect of TLR2 agonists on VSMC migration, proliferation, and viability. Our results show that TLR2 activation by agonists selectively induces IL-6-dependent VSMC migration, which is mediated via p38 mitogen-associated protein kinase (MAPK) and extracellular signal−regulated kinase (ERK) 1/2 pathways, leading to CREB activation and CREB-dependent IL-6 production.
Materials and Methods
Primary VSMCs were isolated from aortas of wild-type (WT) and Tlr2 −/− C57BL/6J mice and cultured in DMEM containing 10% fetal bovine serum. 20 Cells were typically serum starved for 24 hours before treatment with TLR2 ligands. IL-6 levels in culture supernatants were measured by ELISA. Cell viability was measured by 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion assay. Cell proliferation was determined by bromodeoxyuridine incorporation assays. VSMC migration was analyzed using transwell plates with 8-μm pore size. IL-6 promoter activity was examined by transient transfection of VSMCs with IL-6 promoter-luciferase plasmid with or without CREB mutated. After overnight serum starvation, the cells were incubated with pam3CSK4 (P3C4) for 8 hours before harvesting for luciferase activity. Filamentous actin fiber (F-actin) level was examined by fluorescein isothiocyanate−conjugated phalloidin staining. VSMCs transfection with small interfering RNA (siRNA) was performed using a Gene Pulser Xcell Electroporation system (Bio-Rad) or FuGENE 6 (Roche Molecular Biochemicals). Detailed methods are described in the expanded Materials and Methods section in the online-only Data Supplement.
Results

TLR2 Is Functional in VSMCs
To investigate the role of TLRs in the pathphysiology of VSMC, we first assessed whether TLR isoforms were expressed in VSMCs. As with RAW267.7 macrophages, VSMCs expresssed TLR2, TLR3, TLR4, and TLR9 proteins ( Figure I in the online-only Data Supplement). We next investigated whether these TLRs are functional by measuring proinflammatory cytokine production in response to stimulation with the respective ligands. Serum-starved VSMCs were treated with the TLR2 ligand P3C4, TLR3 ligand Poly(I:C), TLR4 ligand lipopolysaccharides, TLR7/8 ligand CL087, or TLR9 ligand CpG ODN for 24 hours and cytokines (IL-6, IL-10, IL-12, and tumor necrosis factor-α) were measured in the culture medium. The ligands of TLR2, TLR3, and TLR4 substantially stimulated IL-6 production, whereas ligands for TLR7/8 and TLR9 did not ( Figure II in the online-only Data Supplement). In contrast, these ligands did not stimulate IL-10, IL-12, or tumor necrosis factor-α production (data not shown).
We next assessed the functional role of TLR2 in IL-6 production in VSMCs. P3C4 induced IL-6 production in VSMCs, which was abrogated by anti-TLR2 but not anti-TLR4 antibodies ( Figure 1A ). In addition, P3C4 time dependently induced IL-6 production in WT but not in Tlr2 −/− VSMCs ( Figure 1B ). Other TLR2 ligands, such as pam2CSK4, follistatin-like 1, and zymosan, also induced IL-6 production in WT but not in Tlr2 Activation of immune cells by P3C4 is mediated through the TLR2 signaling cascade, which involves a number of kinases, notably, p38 MAPK, ERK1/2, c-Jun N-terminal kinases (JNK) 1/2, and phosphatidylinositol 3′-kinase (PI3K). 21 In VSMCs, P3C4 strongly induced the phosphorylation of p38 MAPK, AKT, ERK1/2, and JNK1/2 within 10 minutes and lasted for at least 30 minutes in WT VSMCs but not in Tlr2 −/− VSMCs ( Figure 1D ). These results indicate that the TLR2 signaling cascade in VSMCs is similar to that in immune cells.
TLR2 Is Required for pam3CSK-Induced VSMC Migration
VSMC proliferation, survival, and migration are critical for atherosclerosis progression. 22, 23 We investigated whether TLR2 plays a significant role in these critical functions. 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assays showed that TLR2 ligands did not affect VSMC viability ( Figure IVA in the onlineonly Data Supplement). Cell counting using trypan blue exclusion also showed that TLR2 ligand did not increase cell numbers ( Figure did not affect VSMC differentiation. We next determined whether P3C4 affects VSMC migration. P3C4 significantly increased VSMC migration when compared with endotoxinfree TE buffer (Figure 2A ). To ascertain that TLR2 is involved in P3C4-induced VMSC migration, we used anti-TLR2 neutralization assay. Anti-TLR2 but not anti-TLR4 antibodies abrogated P3C4-induced VMSC migration (Figure 2A) . Furthermore, other TLR2 ligands induced WT but not Tlr2 −/− VSMC migration ( Figure 2B ). These data indicate that TLR2 is essential for VSMC migration. To determine whether random and directed migration contributed to P3C4-induced VSMC migration, we used TE buffer or PDGF-BB in the bottom chambers of transwell plates to assay for random and directed migration, respectively. PDGF-BB, when placed in the bottom chambers, induced directed migration of TE-treated WT and Tlr2 −/− VSMCs to a similar degree ( Figure 2C ), indicating both WT and Tlr2 −/− VSMCs are able to respond to chemoattractant stimulation. The random migration (TE placed in the bottom chambers) of P3C4-treated WT VSMCs was 2-fold that of TE-treated cells ( Figure 2C ). In contrast, P3C4 did not significantly increase random migration of Tlr2 −/− cells ( Figure 2C ). PDGF-BB in the bottom chambers further increased the migration of P3C4-treated WT VSMCs to 3-fold of controls ( Figure 2C ). In response to PDGF-BB, the cellular migration of Tlr2 −/− VSMCs was similar regardless of P3C4 treatment ( Figure 2C ). These results suggest that compared with Tlr2 −/− VSMCs, the enhanced migration of WT VSMCs after P3C4 treatment was a result of increased random and directed migration.
To investigate whether TLR2-mediated VSMC migration is attributable to secretion of soluble promigratory molecules, we used conditioned medium (CM) from P3C4-treated VSMCs, rather than PDGF-BB, as a chemoattractant in transwell migration assays. CM from P3C4-treated WT VSMCs (WT P3C4-CM) dramatically increased migration of WT VSMCs ( Figure 2D ) as compared with control CM (TE-CM). Importantly, WT P3C4-CM enhanced Tlr2 −/− VSMC migration to a similar degree as that of WT cells ( Figure 2D ). The extent of migration induced by WT P3C4-CM was close to that induced by PDGF ( Figure 2D ). In contrast, CM from P3C4-treated Tlr2
−/− VSMCs. To ascertain that VSMC migration is induced by soluble chemotactic factors in WT P3C4-CM, we made serial WT P3C4-CM dilutions and added them to the transwell assay system. VSMC migration increased as the dilutions lessened of WT P3C4-CM (Figure V in the online-only Data Supplement). Taken together, these results indicate that VSMC migration is induced by soluble factors released from VSMCs stimulated by TLR2 agonists. Checkerboard analysis was next performed to confirm that P3C4-CM-mediated VSMC migration was a result of either chemotaxis (directed) or chemokinesis (nondirected; Figure 2E ). P3C4-CM was added to either the upper or lower wells of the transwell chambers, and VSMC migration was quantitated. A significant increase in VSMC migration was observed when P3C4-CM was in the upper or lower chambers ( Figure 2E ), indicating that P3C4-CM can induce both chemotactic and chemokinetic migration. 
IL-6 Is Essential for TLR2-Induced VMSC Migration
IL-6 has been shown to play an important role in regulating VMSC migration. 19, [24] [25] [26] Given that inhibition of TLR2 impaired IL-6 production and VSMC migration (Figures 1  and 2 ), we hypothesized that IL-6 may be a candidate of the soluble factors released into the CM. To test this hypothesis, we evaluated the effect of IL-6 neutralizing antibodies on the migratory activity of P3C4-CM. IL-6 but not IL-12 neutralizing antibodies significantly inhibited P3C4-CM induced WT or Tlr2 −/− VSMC migration. Inhibition of anti−IL-6 antibody on P3C4-CM chemotactic effect was restored by addition of exogenous recombinant mouse IL-6 ( Figure 3A) . To confirm that P3C4-induced VSMC migration is mediated via IL-6 production and secretion, we added IL-6 neutralizing antibodies before stimulation with P3C4. P3C4-induced VMSC migration was blocked by IL-6 but not IL-12 neutralizing antibodies ( Figure 3B ). The ability of P3C4 to induce VMSC migration was lost in Tlr2 −/− VSMCs. However, exogenous recombinant mouse IL-6 restored the migratory effect of P3C4 on Tlr2 −/− VSMCs ( Figure 3C ). Involvement of IL-6 in TLR2-induced VSMC migration was further confirmed by IL-6 siRNA. IL-6 siRNA but not a control small control RNA (scRNA) resulted in a marked reduction of IL-6 production (Figure VI in the online-only Data Supplement) and VSMC migration ( Figure  3D ). Taken together, these results indicate that TLR2 activation-induced VSMC migration is mediated by the release of IL-6 into the extracellular milieu.
TLR2-Induced IL-6 Production and VSMC Migration Is Mediated by p38 MAPK, ERK1/2, and PI3K/AKT
Given that P3C4 activated p38 MAPK, ERK1/2, and JNK1/2, as well as PI3K/AKT ( Figure 1D ), we used pharmacological inhibitors to evaluate the contribution of these kinases to P3C4-induced IL-6 production. Although p38 MAPK inhibitor SB203580, but not SB20219, inhibited phosphorylation of p38 MAPK and AKT ( Figure VII in the online-only Data Supplement), both inhibited p38 MAPK activities and at 10 to 30 μmol/L significantly decreased P3C4-induced IL-6 production by ≈50% in VSMCs ( Figure 4A ). The ERK1/2 inhibitor PD98059 inhibited ERK1/2 phosphorylation , also inhibited P3C4-induced IL-6 production, whereas SP600125, a JNK1/2 inhibitor, had no significant effect ( Figure 4A ). In addition, inhibiting p38 MAPK, ERK1/2, or PI3K activities blocked diverse TLR2 ligandsinduced IL-6 production ( Figure 4B) .
Because IL-6 production participated in P3C4-induced VMSC migration (Figure 3) , we investigated whether these 3 kinases were also involved in VMSC migration. P3C4-induced migration was impaired by p38 MAPK, ERK1/2, or PI3K but not JNK inhibitor in a manner parallel to IL-6 production ( Figure 4C ). These results indicate that TLR2-induced IL-6 production and VSMC migration are signaled via p38 MAPK, ERK1/2, and PI3K/AKT.
CREB Activation Is Pivotal for P3C4-Induced IL-6 Production and VSMC Migration
IL-6 promoter contains several cis-elements and could be activated by cognate transcription factors, including CREB, nuclear factor-κB, and activating transcription factor 2. 27 We determined whether these transcription factors are activated in P3C4-treated VSMCs. P3C4 induced phosphorylation of CREB, NF-κB p65 (Ser536), and activating transcription factor 2 in VMSCs within 10 minutes and lasted for at least 30 minutes, which was abrogated in Tlr2 −/− VSMCs ( Figure  5A ). Because both p38 MAPK and ERK1/2 signaling pathways were involved in P3C4-induced IL-6 production ( Figure  4) , we investigated whether p38 MAPK and ERK1/2 signaling are required for P3C4-induced activation of CREB, nuclear factor-κB p65, and activating transcription factor 2. Interestingly, inhibition of p38 MAPK or ERK1/2 significantly decreased phosphorylation of CREB but not nuclear factor-κB p65 (Ser536) or activating transcription factor 2 ( Figure 5B ), suggesting that P3C4-stimulated CREB phosphorylation is mediated through p38 MAPK and ERK1/2.
CREB was reported to play a critical role in VSMC migration. 17, 19, 28 To determine whether CREB is involved in P3C4-induced IL-6 expression and VSMC migration, we used CREB siRNA to silence CREB expression ( Figure  VIII in the online-only Data Supplement) and analyzed IL-6 expression. Silencing of CREB resulted in a marked reduction of IL-6 production, whereas a control scRNA did not ( Figure  5C ). To determine whether TLR2 directly activates IL-6 transcription in a CREB-dependent manner, we evaluated the effect of P3C4 on IL-6 promoter activity. P3C4 increased IL-6 promoter activity by 4-fold, which was abrogated by mutation of cAMP response elements cis-acting element ( Figure  5D ). P3C4-induced IL-6 promoter activity was inhibited by CREB siRNA and not by the control scRNA ( Figure 5E ). Furthermore, P3C4-induced VSMC migration was blocked by CREB siRNA but not control scRNA ( Figure 5F ). These results provide evidence for the requirement of CREB binding to cAMP response elements for P3C4-induced IL-6 expression and IL-6-mediated VSMC migration.
P3C4 Induces Assembly of Actin Stress Fiber
As actin cytoskeleton reorganization is crucial for cell migration, we investigated the effect of P3C4 on actin skeleton of VSMCs by using fluorescein isothiocyanate−conjugated phalloidin staining for F-actin. P3C4 induced pronounced actin stress fibers and lamellipodia formation, which was blocked by IL-6 but not IL-12 neutralizing antibodies ( Figure 6A ). P3C4 failed to induce organized F-actin in Tlr2 −/− VSMCs, which was rescued by addition of IL-6 ( Figure 6B , upper row). To gain further insight into the role of IL-6 in P3C4-induced actin polymerization, Tlr2 −/− VSMCs were incubated with WT P3C4-CM in the presence or absence of IL-6 antibodies for 24 hours, and F-actin level was examined by fluorescein isothiocyanate−conjugated phalloidin staining. P3C4-CM from WT VSMCs dramatically increased actin fibers of Tlr2 −/− VSMCs ( Figure 6B , lower panel) as compared with control CM (TE-CM). The neutralizing antibody of IL-6 but not IL-12 substantially inhibited F-actin formation in Tlr2 −/− VSMC in response to P3C4-CM from WT VSMCs. Collectively, these results indicate that P3C4-induced F-actin and lamellipodia formation in VSMCs is mediated via release of IL-6 in the CM.
Rac1 is a member of the Rho family of small GTP-binding proteins, which regulate assembly of actin cytoskeletal structures associated with cell migration. 29 To investigate the role of Rac1 in TLR2-induced IL-6 production and VSMC migration, we evaluated the effect of NSC23766, a Rac1 inhibitor, on VSMC migration. NSC23766 significantly reduced P3C4-and IL-6-induced migration ( Figure 6C ). However, NSC23766 did not inhibit P3C4-induced IL-6 production ( Figure IX in the online-only Data Supplement); NSC23766 also significantly attenuated P3C4-or IL-6-induced assembly of VSMC actin cytoskeleton ( Figure 6D ). To further examine the role of Rac1 in TLR2-mediated VSMC migration, siRNA for mouse Rac1 was used to knockdown Rac1 expression in VSMCs (Figure X in the online-only Data Supplement). P3C4-induced VSMC migration was impaired in cells transfected with specific Rac1 siRNA but not control scRNA ( Figure 6E ). These results suggest that Rac1 participates in P3C4-induced VSMC migration.
Discussion
Atherosclerosis is a chronic inflammatory response of the arterial injury by chemical insults (hyperglycemia), modified low-density lipoprotein, or mechanical stress. 1 In the early atherogenic process, arterial endothelial cells and macrophages proceed to induce the formation of lipid peroxides, which results in the formation of foam cells and fatty streak. In the center of an atherosclerotic lesion, foam cells and extracellular lipid droplets form a core region that is surrounded by a cap of SMCs and a collagen-rich matrix.
1 Subsequently, the inflammatory response in the microenvironment of the atherosclerotic lesion may stimulate migration of VSMCs; however, the full spectrum of agonists that stimulate VSMCs has not been determined. Despite substantial evidence supporting the pathogenic role of TLR2 in atherosclerosis via its actions on endothelial cell activation or macrophage recruitment, [30] [31] [32] little is known about its relation to VSMC function, such as proliferation and migration, and the underlying mechanisms. Heat shock protein 60, fibronectin, oxidized low-density lipoprotein, and free fatty acids, which have been reported to be TLR2 ligands in vitro, −/− VSMCs were treated with pam3CSK4 for the indicated times; or B, After pretreating VSMCs with different concentrations of SB203580 or PD98059 for 30 minutes, cells were stimulated with pam3CSK4 for 20 minutes. Cell lysates were immunoblotted with antibodies for CREB, phospho-CREB, activating transcription factor 2 (ATF2), phospho-ATF2, nuclear factor-κB p65, phospho-nuclear factor-κB p65 (Ser536), or α-actin. The experiments were repeated 3 times with similar results. C, VSMCs were transfected with the indicated small interfering RNAs (siRNAs) for 24 hours and then serum depleted for 24 hours. Cells were incubated with pam3CSK4 (P3C4) for 24 hours and IL-6 level in culture supernatants was measured by ELISA. D and E, IL-6 promoter activity was measured by IL-6 promoter-luciferase assay. D, VSMCs were transfected with the indicated siRNAs and IL-6 promoter-luciferase plasmid. E, VSMCs were transfected with either IL-6 promoter-luciferase plasmid or cAMP response elements−binding mutant. After 24 hours serum starvation, the cells were incubated with P3C4 for 8 hours. Luciferase activity was measured. F, VSMCs were transfected with the indicated siRNAs. Quiesced cells were incubated with P3C4 for 24 hours and migration assays performed as in Figure 2A . Data in C−F represent mean+SD of 3 experiments. are found in plaques of apolipoprotein E−deficient mice and human coronary bypass grafts. 1 Thus, these molecules are likely endogenous ligands for TLR2. In the present study, we demonstrate that TLR2 activation drives VSMC migration by an IL-6-dependent mechanism. Ligand-activated TLR2 promotes IL-6 expression at the transcription level primarily via CREB transactivation, and IL-6 released into the extracellular milieu induces VSMC migration through Rac1-mediated F-actin and lamellipodia formation. Our results not only confirm that TLR2 signals via multiple signaling kinases, such as p38 MAPK and ERK1/2, but also provide novel evidence for the involvement of these signaling pathways in TLR2-driven IL-6 production and VSMC migration. Our results provide new insights into the mechanism underlying TLR2-induced VSMC migration as illustrated in Figure 6F .
IL-6, a pleiotropic cytokine, is a key molecule in chronic inflammation and has been implicated in the progression of atherosclerosis. IL-6 production was increased in VSMCs in response to stimulators, such as PDGF-BB, thrombin, angiotensin II, and 15(S)-hydroxyeicosatertraenoic acid. IL-6 stimulation was reported to be important in VSMC migration and proliferation. 19, [24] [25] [26] Much evidence showed that activation of TLR2 by synthetic ligand P3C4 or pathogen infection induced IL-6 production in atherosclerotic lesions. 6, 33 Our results reveal that TLR2 ligands induce IL-6 but not other proinflammatory cytokines, such as IL-12, IL-10, and tumor necrosis factor-α in VSMCs. Thus, IL-6 is the predominant effector cytokine for TLR2-mediated VSMC migration. This notion is supported by abrogation of TLR2-induced VSMC migration by IL-6 neutralization antibodies (Figure 3 ). In addition, CM from P3C4-treated WT VSMCs promoted migration of WT and Tlr2 −/− VSMC, as well as actin reorganization ( Figures  2C−2E, 3C , and 6B). These results suggest that TLR2-mediated IL-6 secretion acts in an autocrine or paracrine manner to regulate VSMC migration and, thereby, modulate the disease progression.
Atherosclerosis progression is highly correlated with VSMC migration, which requires a coordinated rearrangement of the actin cytoskeleton. The migratory response can be induced by signals from chemoattractants and growth factors, as well as effective agonists. As demonstrated in Figures  3 and 6 , P3C4 induced IL-6 secretion to act as chemoattractant, thereby promoting VSMC migration. Though chemoattractants were reported to induce VSMC migration by actin reorganization-dependent and -independent mechanisms, our results demonstrate that VSMC migration induced by P3C4, IL-6, and P3C4-CM of WT VSMC is accompanied by cytoskeletal rearrangements. Rac1 activation is reported to play an important role in regulating cell migration, actin-based cytoskeletal rearrangements, and lamellipodia formation. 34, 35 Experiments with pharmacological inhibitors and siRNA revealed that inhibition of Rac1 activity and expression attenuated P3C4-induced VSMC cytoskeletal rearrangement and migratory activity ( Figure 6 ; Figure IX in the online-only Data Supplement), which underscores the important role of Rac1 in TLR2-induced VSMC migration.
CREB is a widely expressed nuclear transcription factor and plays an important role in gene regulation. Its activity appears to depend on phosphorylation of serine-133. Several types of serine/threonine kinases, including calcium/calmodulin-dependent protein kinases, MAPKs, PI3K, protein kinase A, protein kinase G, and pp90 ribosomal S6 kinase, were reported to phosphorylate CREB-1 on serine-133. 14, 16 Recent reports indicate that p38 MAPK and ERK1/2 signaling are involved in arachidonic acid-stimulated CREB phosphorylation, 15 whereas p38 MAPK, ERK1/2, and JNK1/2 are involved in 15(S)-hydroxyeicosatertraenoic acid-induced CREB activation. 19 Our results show that p38 MAPK and ERK1/2 participated in TLR2 agonist-induced CREB phosphorylation. Furthermore, CREB-mediated IL-6 production is required for TLR2-mediated VSMC migration. Collectively, our results indicate that TLR2 induces VSMC migration by triggering IL-6 production, which is signaled via p38 MAPKand ERK1/2-dependent activation of CREB.
The involvement of CREB in the pathogenesis of atheroscleosis has been the subject of intense investigation. However, the precise role of CREB in VSMC proliferation and migration has been controversial. 15, [17] [18] [19] 28, 36 CREB activation by thrombin, tumor necrosis factor-α, arachidonic acid, and 15(S)-hydroxyeicosatertraenoic acid was reported to stimulate VSMC migration and proliferation. 15, 17, 19, 36 However, CREB content and activity were shown to correlate negatively with VSMC migration and proliferation. 18, 28 These differences may be attributed to different cell contexts and signaling pathways. Our findings demonstrate that in VSMCs CREB positively regulates TLR2-induced cell migration.
TLRs are principal receptors in the innate immune system that provide a mechanistic link between infection, inflammation, and atherosclerosis. Our results reveal that several TLRs are expressed in VSMCs, among which only 3, TLR2, TLR3, and TLR4, are involved in induction of IL-6 production. In the present study, we used molecular genetic and biochemical approaches to demonstrate that TLR2 signaling mediates VSMC migration but not proliferation. In contrast, the TLR4 signaling induces not only VSMC migration but also VSMC proliferation. 37, 38 It was reported that activation of TLR4 by high-mobility group box-1 induces VSMC migration through PI3K/AKT signaling pathway. 38 It remains unknown whether high-mobility group box-1−induced VSMC migration requires CREB or IL-6. Unexpectedly, TLR3 signaling had no effect on VSMC migration (our unpublished data). But investigation by Yang et al 39 revealed that TLR3 signaling evokes a proinflammatory and proliferative phenotype in human VSMCs. Furthermore, emerging results indicate that TLR3 has a protective role in the arterial well. 40 Collectively, these observations suggest that different TLRs play distinct roles in mediating the involvement of VSMCs in the pathogenesis of atherosclerosis and cardiovascular diseases.
In summary, TLR2 is pivotal in VSMC migration, which contributes to the progression of atherosclerosis. We have provided evidence that TLR2 promotes VSMC migration through CREB-mediated IL-6 production signaled via p38 MAPK and ERK1/2. These findings provide mechanistic insights into the essential role of TLR2 in atherosclerosis as demonstrated by reduction of atherosclerosis in Apoe −/− and LDLr −/− mice in which TLR2 was silenced. 6, 30, 31 These findings will be valuable for developing new therapeutic strategies against vascular diseases.
